Maynard Um
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $50 at Jefferies
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $54 at Guggenheim
-
-
-
-
-
-
-
FDA extends review of Travere's FILSPARI application for FSGS to 2026
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $48 at Citi, New Catalyst Watch
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
H.C. Wainwright Assumes Travere Therapeutics (TVTX) at Buy
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Tops Q1 EPS by 36c
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

